OrbusNeich Medical Group Holdings Limited Stock

Equities

6929

KYG6773B1005

Medical Equipment, Supplies & Distribution

Market Closed - Hong Kong S.E. 04:08:20 2024-04-26 EDT 5-day change 1st Jan Change
3.83 HKD +4.08% Intraday chart for OrbusNeich Medical Group Holdings Limited +6.09% -45.67%

Financials

Sales 2024 * 1.28B 176M 1.38B 241M Sales 2025 * 1.48B 205M 1.6B 280M Capitalization 2.94B 405M 3.17B 554M
Net income 2024 * 336M 46.37M 363M 63.39M Net income 2025 * 386M 53.27M 417M 72.83M EV / Sales 2024 * 0.8 x
Net cash position 2024 * 1.91B 264M 2.07B 361M Net cash position 2025 * 2.33B 322M 2.52B 440M EV / Sales 2025 * 0.41 x
P/E ratio 2024 *
9.01 x
P/E ratio 2025 *
7.54 x
Employees 1,249
Yield 2024 *
2.54%
Yield 2025 *
2.85%
Free-Float 36.97%
More Fundamentals * Assessed data
Dynamic Chart
OrbusNeich Medical Group’s Profit Up 144% in 2023 MT
OrbusNeich Medical Group Holdings Limited Proposes Final Dividend for the Year Ended December 31, 2023, Payable on 28 June 2024 CI
OrbusNeich Medical Group Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI
OrbusNeich Medical Seeks M&A Opportunities CI
OrbusNeich Medical Group Holdings Limited acquired SJ Medicare Co. Ltd. CI
OrbusNeich Expects More Than Doubling of 2023 Profit MT
Certain Ordinary Shares of OrbusNeich Medical Group Holdings Limited are subject to a Lock-Up Agreement Ending on 22-DEC-2023. CI
OrbusNeich Medical Subsidiary Buys 84% Stake in Indonesian Medical Device Maker MT
OrbusNeich Medical to Acquire Eucatech for 2.4 Million Euros MT
OrbusNeich Medical Group Holdings Limited acquired Eucatech AG for ?2.4 million. CI
OrbusNeich Medical Extends Term of Exclusive US Distributor of Products to 2027 MT
Orbusneich Medical Group Holdings Limited and Cardiovascular Systems, Inc. Enters into an Amendment to Distribution Agreement CI
OrbusNeich Medical Group Holdings Limited(SEHK:6929) added to S&P Global BMI Index CI
OrbusNeich Medical Group Holdings Limited Announces Retirement of Ching Chung John Chow from the Group of All Executive Roles and Has Been Re-Designated as Non-Executive Director with effect from September 7, 2023 CI
OrbusNeich Medical Group Holdings Limited Reports Earnings Results for the Half Year Ended June 30, 2023 CI
More news
1 day+4.08%
1 week+6.09%
Current month+18.94%
1 month+26.40%
3 months-30.49%
6 months-56.82%
Current year-45.67%
More quotes
1 week
3.43
Extreme 3.43
3.88
1 month
3.07
Extreme 3.07
3.88
Current year
3.01
Extreme 3.01
7.06
1 year
3.01
Extreme 3.01
14.82
3 years
3.01
Extreme 3.01
16.86
5 years
3.01
Extreme 3.01
16.86
10 years
3.01
Extreme 3.01
16.86
More quotes
Managers TitleAgeSince
Chief Executive Officer 59 21-07-21
Director of Finance/CFO 43 21-07-21
Chief Tech/Sci/R&D Officer 61 -
Members of the board TitleAgeSince
Chief Executive Officer 59 21-07-21
Director/Board Member 40 21-09-28
Director/Board Member 48 21-09-28
More insiders
Date Price Change Volume
24-04-26 3.83 +4.08% 510,500
24-04-25 3.68 +0.55% 82,000
24-04-24 3.66 +6.40% 230,500
24-04-23 3.44 -3.64% 90,000
24-04-22 3.57 -1.11% 100,500

Delayed Quote Hong Kong S.E., April 26, 2024 at 04:08 am

More quotes
OrbusNeich Medical Group Holdings Ltd is an investment holding company principally engaged in the development, production and sales of medical equipment and machineries. The Company is engaged in the design, development, manufacture, distribution and sale of interventional medical devices for the treatment of coronary heart disease and peripheral vascular diseases. The Company's main products include percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) balloons. In addition, the Company's products also include semi-compliant balloons and scoring balloons for pre-dilatation and lesion preparation, coronary stents for implantation, non-compliant balloons for post-dilatation and specialty catheters. The Company mainly conducts its businesses in domestic and overseas markets.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
3.545 CNY
Average target price
6.393 CNY
Spread / Average Target
+80.33%
Consensus

Quarterly revenue - Rate of surprise